These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26580582)

  • 1. Role of Neprilysin Inhibitors in Heart Failure.
    Salazar Adum JP; Arora R
    Am J Ther; 2017; 24(6):e737-e743. PubMed ID: 26580582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.
    Bartell N; Frishman WH
    Cardiol Rev; 2017; 25(6):315-320. PubMed ID: 28984670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
    Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARADIGM-HF--the experts' discussion.
    Jessup M; Fox KA; Komajda M; McMurray JJ; Packer M
    N Engl J Med; 2014 Sep; 371(11):e15. PubMed ID: 25184757
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
    Krum H
    Circulation; 2015 Jan; 131(1):11-2. PubMed ID: 25411157
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
    McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
    N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Vilela-Martin JF
    Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
    Packer M; Claggett B; Lefkowitz MP; McMurray JJV; Rouleau JL; Solomon SD; Zile MR
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):547-554. PubMed ID: 29661699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
    Pham AQ; Patel Y; Gallagher B
    J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
    Ferrari L; Sada S;
    Intern Emerg Med; 2015 Apr; 10(3):369-71. PubMed ID: 25537439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.